Categories AlphaGraphs, Earnings, Other Industries

LDOS Earnings: Highlights of Leidos Holdings’ Q4 2022 results

Leidos Holdings, Inc. (NYSE: LDOS) on Tuesday reported higher earnings and revenues for the fourth quarter of 2022. The company also provided guidance for fiscal 2023.

Leidos Holdings Q4 2022 earnings infographic

At $3.69 billion, fourth-quarter revenues were up 6% year-over-year. Revenues of the Civil and Health segments increased in double-digits while Defense Solutions remained unchanged.

Unadjusted net income increased to $180 million or $1.28 per share in the December quarter from $176 million or $1.23 per share in the prior-year period. Adjusted profit was $1.83 per share, up 17% from last year.

For fiscal 2023, the company expects revenues to be in the range of $14.7 billion to $15.1 billion, and adjusted earnings per share to be between $6.40 and 6.80.

Prior Performance

  • Leidos-Holdings-Q3-2022-Earnings-Infographic

_________________________________________________________________________________________________________________

Stocks you may like:

Apple (AAPL) Stock

Microsoft (MSFT) Stock

Alphabet (GOOGL) Stock

International Business Machines Corp. (IBM) Stock

_________________________________________________________________________________________________________________

Most Popular

Key takeaways from JM Smucker’s (SJM) Q4 2025 earnings report

Shares of The J.M. Smucker Co. (NYSE: SJM) plunged 15% on Tuesday after the company delivered mixed results for the fourth quarter of 2025. While earnings came ahead of expectations,

J.M. Smucker (SJM) Q4 2025 Earnings: Key financials and quarterly highlights

The J.M. Smucker Co. (NYSE: SJM) reported its fourth quarter 2025 earnings results today. Net sales was $2.1 billion, down 3% year-over-year. Comparable net sales decreased 1%. Net loss was

Plus Therapeutics CEO: Lead candidate REYOBIQ demonstrates strong safety and efficacy in early trials

Plus Therapeutics (NASDAQ: PSTV) is a pharmaceutical company engaged in the development of targeted radiotherapeutics for difficult-to-treat cancers. Currently, it is advancing a pipeline of product candidates with lead programs

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top